<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39359418</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2674-0095</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in molecular medicine</Title><ISOAbbreviation>Front Mol Med</ISOAbbreviation></Journal><ArticleTitle>DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome.</ArticleTitle><Pagination><StartPage>1461151</StartPage><MedlinePgn>1461151</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1461151</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmmed.2024.1461151</ELocationID><Abstract><AbstractText>Cytokine release syndrome is a serious complication of chimeric antigen receptor-T cell therapy and is triggered by excessive secretion of inflammatory cytokines by chimeric T cells which could be fatal. Following an inquiry into the molecular mechanisms orchestrating cytokine release syndrome, we hypothesize that DeltaRex-G, a tumor targeted retrovector encoding a cytocidal CCNG1 inhibitor gene, may be a viable treatment option for corticosteroid-resistant cytokine release syndrome. DeltaRex-G received United States Food and Drug Administration Emergency Use Authorization to treat Covid-19-induced acute respiratory distress syndrome, which is due to hyperactivated immune cells. A brief administration of DeltaRex-G would inhibit a certain proportion of hyperactive chimeric T cells, consequently reducing cytokine release while retaining chimeric T cell efficacy.</AbstractText><CopyrightInformation>Copyright © 2024 Haroun and Gordon.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haroun</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Erlinda M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Sarcoma Oncology Research Center, Santa Monica CA, Aveni Foundation, Santa Monica, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Med</MedlineTA><NlmUniqueID>9918402378306676</NlmUniqueID><ISSNLinking>2674-0095</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAR-T cell therapy</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">DeltaRex-G</Keyword><Keyword MajorTopicYN="N">acute respiratory disease</Keyword><Keyword MajorTopicYN="N">cytokine release syndrome</Keyword></KeywordList><CoiStatement>EMG is co-inventor of the targeted gene delivery system represented by DeltaRex-G which was created and developed at USC Keck School of Medicine, Los Angeles, CA. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39359418</ArticleId><ArticleId IdType="pmc">PMC11445129</ArticleId><ArticleId IdType="doi">10.3389/fmmed.2024.1461151</ArticleId><ArticleId IdType="pii">1461151</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
A Study to Evaluate the Safety, TolerabilityEfficacy, Preliminary (2023). Pharmacodynamics and immunogenicity of universal CNK-ut cells in patients with advanced solid tumors. Available at: https://clinicaltrials.gov/study/NCT05976906.
</Citation></Reference><Reference><Citation>Adusumilli P. S., Cherkassky L., Villena-Vargas J., Colovos C., Servais E., Plotkin J., et al. (2014). Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6 (261), 261ra151. 10.1126/scitranslmed.3010162</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3010162</ArticleId><ArticleId IdType="pmc">PMC4373413</ArticleId><ArticleId IdType="pubmed">25378643</ArticleId></ArticleIdList></Reference><Reference><Citation>
An Open (2022). Single-arm clinical study of autologous T cells (CAR-T) targeting B7-H3 chimeric antigen receptor gene in the treatment of patients with advanced gastrointestinal tumors. Available at: https://clinicaltrials.gov/study/NCT05515185.
</Citation></Reference><Reference><Citation>
An Open Label (2019). “Single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and cytokinetics of autologous humanized anti-claudin18,” in 2 chimeric antigen receptor T cell in advanced solid tumor subjects. Available at: https://clinicaltrials.gov/study/NCT03874897.
</Citation></Reference><Reference><Citation>
A Phase1/phase2, Single-arm (2023). Open-label study of RD14-01 in patients with advanced solid tumors. Available at: https://clinicaltrials.gov/study/NCT05748938.
</Citation></Reference><Reference><Citation>
A Phase Ia/Ib (2022). Open-label, single-arm, dose-escalation and expansion study of specific dual-targeting VEGFR1 and PD-L1 CAR-T in cancer patients with pleural or peritoneal metastases. Available at: https://clinicaltrials.gov/study/NCT05477927.
</Citation></Reference><Reference><Citation>
A Phase I Investigation of the Safety (2019). Tolerability and immunological effects of T Lymphocytes transduced with an anti-lewis Y (LeY) chimeric antigen receptor gene (LeY-CAR-T) in patients with LeY antigen expressing advanced solid tumours. Available at: https://clinicaltrials.gov/study/NCT03851146.
</Citation></Reference><Reference><Citation>
A Phase I Trial to Assess Safety (2020). Tolerability and anti-tumor activity of autologous T cell modified chimeric antigen receptor (CAR) (CCT303-406) in patients with relapsed or refractory HER2 positive solid tumors. Available at: https://clinicaltrials.gov/study/NCT04511871.
</Citation></Reference><Reference><Citation>Asmamaw D. T., Tiruneh G. /M. M., Dessie Terefe G., Tadele Admasu F., Wale Tesega W., Chekol Abebe E. (2022). Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum. Vaccines and Immunother. 18 (6), 2114254. 10.1080/21645515.2022.2114254</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2114254</ArticleId><ArticleId IdType="pmc">PMC9746433</ArticleId><ArticleId IdType="pubmed">36094837</ArticleId></ArticleIdList></Reference><Reference><Citation>
An exploratory study of αpd1-MSLN-CAR T cells secreting PD-1 nanobodies for the treatment of MSLN-positive advanced solid tumors (2020). Available at: https://clinicaltrials.gov/study/NCT04503980

</Citation></Reference><Reference><Citation>
An exploratory study of αpd1-MSLN-CAR T cells secreting PD-1 nanobodies for the treatment of MSLN-positive advanced solid tumors (2022). Available at: https://clinicaltrials.gov/study/NCT05373147

</Citation></Reference><Reference><Citation>
A First in human phase I trial of binary oncolytic adenovirus in combination with HER2-specific autologous CAR T cells in patients with advanced HER2 positive solid tumors (2018). Available at: https://clinicaltrials.gov/study/NCT03740256

</Citation></Reference><Reference><Citation>
A clinical study on the safety and preliminary efficacy of IMC008 in the treatment of CLDN18.2- positive advanced solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT05837299

</Citation></Reference><Reference><Citation>
An exploratory clinical study evaluating the safety and efficacy of anti-CEA-CAR-T cells injection in patients with CEA+ locally advanced and/or metastatic solid tumors (2023a). Available at: https://clinicaltrials.gov/study/NCT06013111

</Citation></Reference><Reference><Citation>
An exploratory clinical study evaluating the safety and efficacy of anti-HER2-CAR-T cells injection in patients with HER2+ locally advanced and/or metastatic solid tumors (2023b). Available at: https://clinicaltrials.gov/study/NCT06101082

</Citation></Reference><Reference><Citation>
A phase I/II study administering peripheral Blood Lymphocytes transduced with a CD70-binding chimeric antigen receptor to patients with CD70-expressing cancers (2016). Available at: https://clinicaltrials.gov/study/NCT02830724

</Citation></Reference><Reference><Citation>
A safety and efficacy clinical study of CEA-targeted CAR-T therapy for CEA-positive advanced malignant solid tumors (2022). Available at: https://clinicaltrials.gov/study/NCT05415475

</Citation></Reference><Reference><Citation>
A safety and efficacy clinical study of CEA-targeted CAR-T therapy forCEA-positive advanced/metastatic malignant solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT06010862

</Citation></Reference><Reference><Citation>
A seamless phase 1/2 study to evaluate the safety and efficacy of A2B694, an autologous logic-gated TmodTM CAR T, in Heterozygous HLA-A*02 adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express MSLN and have lost HLA-A*02 expression (2023). Available at: https://clinicaltrials.gov/study/NCT06051695

</Citation></Reference><Reference><Citation>
A phase 1 dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic solid tumors (2022). Available at: https://clinicaltrials.gov/study/NCT05239143

</Citation></Reference><Reference><Citation>
A phase 1 study of FT825/ONO-8250, an off-the-shelf CAR T-cell therapy, with or without monoclonal antibodies (2024). in HER2-Positive or other advanced solid tumors
Available at: https://clinicaltrials.gov/study/NCT06241456

</Citation></Reference><Reference><Citation>
A phase 1 study to assess the safety and efficacy of LYL797, ROR1-targeting CAR T cells (2022). in Adults with relapsed and/or refractory solid-tumor malignancies
Available at: https://clinicaltrials.gov/study/NCT05274451

</Citation></Reference><Reference><Citation>
A phase 1/2 study to evaluate the safety and efficacy of A2B530, an autologous logic-gated TmodTM chimeric antigen receptor T cell (CAR T), in heterozygous HLA-A*02 adult subjects with recurrent unresectable (2023). Local. Adv. or Metastatic Solid Tumors That Express CEA Have Lost HLA-A*02 Expr.
Available at: https://clinicaltrials.gov/study/NCT05736731

</Citation></Reference><Reference><Citation>
A single-arm, open, exploratory clinical study evaluating the safety and efficacy of EGFR/B7H3 CAR-T in patients with EGFR/B7H3-positive advanced solid tumors (lung and triple-negative breast cancer) (2022). Available at: https://clinicaltrials.gov/study/NCT05341492

</Citation></Reference><Reference><Citation>
A phase I clinical study of anti-CEA CAR-T therapy in the treatment of CEA-positive advanced malignant solid tumors. (2022a) Available at: https://clinicaltrials.gov/study/NCT05396300

</Citation></Reference><Reference><Citation>
A phase I clinical study of CD70-targeting CAR-T therapy in the treatment of CD70-positive advanced/metastatic solid tumors (2022b). Available at: https://clinicaltrials.gov/study/NCT05420545

</Citation></Reference><Reference><Citation>
A phase I clinical study of CD70-targeting CAR-T therapy in the treatment of CD70-positive advanced/metastatic solid tumors. (2022c). Available at: https://clinicaltrials.gov/study/NCT05518253

</Citation></Reference><Reference><Citation>
A single-center exploratory clinical study to evaluate the safety and efficacy of RD133 in subjects with relapsed or refractory MSLN-positive solid tumors (2021). Available at: https://clinicaltrials.gov/study/NCT05141253

</Citation></Reference><Reference><Citation>
A phase I clinical study to assess the safety and efficacy of CD70-targeted CAR-T in the treatment of CD70-positive advanced/metastatic solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT06010875

</Citation></Reference><Reference><Citation>
A phase I clinical study to assess the safety and tolerability of CD70-targeting CAR-T in the treatment of CD70-positive advanced/metastatic solid tumors (2022d). Available at: https://clinicaltrials.gov/study/NCT05468190

</Citation></Reference><Reference><Citation>
B7-H3-Specific chimeric antigen receptor autologous T-cell therapy for pediatric patients with solid tumors (3CAR) (2021). Available at: https://clinicaltrials.gov/study/NCT04897321

</Citation></Reference><Reference><Citation>Bajwa A., Zhao Q., Geer M. J., Mian A., Lin C., Frame D., et al. (2024). Efficacy of Siltuximab for chimeric antigen receptor T-cell therapy toxicities – a multicenter retrospective Analysis. Transplant. Cell. Ther. 30 (2), S201–S202. 10.1016/j.jtct.2023.12.261</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtct.2023.12.261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruckner H. W., Chawla S. P., Omelchenko N., Brigham D. A., Gordon E. M. (2023). Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast. Front. Mol. Med. 3, 1105680. 10.3389/fmmed.2023.1105680</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmmed.2023.1105680</ArticleId><ArticleId IdType="pmc">PMC11285576</ArticleId><ArticleId IdType="pubmed">39086675</ArticleId></ArticleIdList></Reference><Reference><Citation>Brudno J. N., Kochenderfer J. N. (2016). Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127 (26), 3321–3330. 10.1182/blood-2016-04-703751</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-04-703751</ArticleId><ArticleId IdType="pmc">PMC4929924</ArticleId><ArticleId IdType="pubmed">27207799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla S. P., Bruckner H., Morse M. A., Assudani N., Hall F. L., Gordon E. M. (2019). A phase I-II study using rexin-G tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer. Mol. Ther. - Oncolytics 12, 56–67. 10.1016/j.omto.2018.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2018.12.005</ArticleId><ArticleId IdType="pmc">PMC6348982</ArticleId><ArticleId IdType="pubmed">30705966</ArticleId></ArticleIdList></Reference><Reference><Citation>
Chawla S. P., Chawla N. S., Quon D., Chua-Alcala V., Blackwelder W. C., Hall F. L., et al.  (2016). An advanced phase 1/2 study using an XC-targeted gene therapy vector for chemotherapy resistant sarcoma. Sarcoma Res. Int.
3 (1), 1024. Available at: https://austinpublishinggroup.com/sarcoma/fulltext/sarcoma-v3-id1024.pdf.
</Citation></Reference><Reference><Citation>Chawla S. P., Wong S., Quon D., Moradkhani A., Chua V. S., Brigham D. A., et al. (2022). Three year results of Blessed: expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130). Front. Mol. Med. 2, 1092286. 10.3389/fmmed.2022.1092286</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmmed.2022.1092286</ArticleId><ArticleId IdType="pmc">PMC11285611</ArticleId><ArticleId IdType="pubmed">39086973</ArticleId></ArticleIdList></Reference><Reference><Citation>
Chimeric Antigen Receptor T Lymphocytes (CAR-T) (2022). Targeting CEA in the treatment of CEA positive clinical study of advanced malignant solid tumors. Available at: https://clinicaltrials.gov/study/NCT05538195.
</Citation></Reference><Reference><Citation>
Clinical study to evaluate the safety and efficacy of U87 CART in treatment of advanced solid tumor (2022). Available at: https://clinicaltrials.gov/study/NCT05605197

</Citation></Reference><Reference><Citation>
Clinical trial to evaluate the safety and efficacy of IM96 CAR-T cells therapy in patients with advanced digestive system neoplasms (2022). Available at: https://clinicaltrials.gov/study/NCT05287165

</Citation></Reference><Reference><Citation>
Clinical Study of CLDN18 (2022). 2-targeting chimeric antigen receptor-modified autologous T cells in advanced solid tumors with positive CLDN18, 2. Available at: https://clinicaltrials.gov/study/NCT05472857.
</Citation></Reference><Reference><Citation>
Efficacy and Safety of Claudin18 (2022). 2CAR-T Adv. Pancreat. Cancer Gastric Carcinoma. Available at: https://clinicaltrials.gov/study/NCT05620732.
</Citation></Reference><Reference><Citation>
Exploratory clinical study of PD-1 knockout targeting MUC1 CAR-T cells (AJMUC1) in the treatment of MUC1-positive advanced breast cancer (2022). Available at: https://clinicaltrials.gov/study/NCT05812326

</Citation></Reference><Reference><Citation>
Exploratory clinical trial on the safety, efficacy, and pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in claudin 18.2 positive advanced solid malignant tumors: a Single center, Single arm, Dose-increasing Trial (2023a). Available at: https://clinicaltrials.gov/study/NCT05952375

</Citation></Reference><Reference><Citation>
Exploratory clinical trial on the safety, tolerability, efficacy, and pharmacokinetics of XKDCT080 in GCC-positive recurrent or refractory solid tumors with Single center, Single arm, and dose escalation.(2023b). Available at: https://clinicaltrials.gov/study/NCT05875402

</Citation></Reference><Reference><Citation>
Exploratory study of MSLN-CAR T cells secreting PD1/CTLA-4 nanoantibody for the treatment of advanced solid tumors.(2024). Available at: https://clinicaltrials.gov/study/NCT06248697

</Citation></Reference><Reference><Citation>
Exploratory study on the treatment of advanced solid tumor with non-viral vector multi-targeted autosecretory multifunctional antibody CAR-T cell injection (2024). Available at: https://clinicaltrials.gov/study/NCT06327997

</Citation></Reference><Reference><Citation>
An exploratory study on the treatment of advanced solid tumors by secretory PD1 nanoantibody targeting mesothelin fast CAR T cells. 2024. 
Available at: https://clinicaltrials.gov/study/NCT06249256

</Citation></Reference><Reference><Citation>Ferreros P., Trapero I. (2022). Interleukin inhibitors in cytokine release syndrome and neurotoxicity secondary to CAR-T therapy. Diseases 10 (3), 41. 10.3390/diseases10030041</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases10030041</ArticleId><ArticleId IdType="pmc">PMC9326641</ArticleId><ArticleId IdType="pubmed">35892735</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fih A., Arm S. (2022). Open label study to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of autologous CAR T cells targeting BT-001. Patients Adv. Solid Tumors. Available at: https://clinicaltrials.gov/study/NCT05621486.
</Citation></Reference><Reference><Citation>Freyer C. W., Porter D. L. (2020). Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J. Allergy Clin. Immunol. 146 (5), 940–948. 10.1016/j.jaci.2020.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.07.025</ArticleId><ArticleId IdType="pubmed">32771558</ArticleId></ArticleIdList></Reference><Reference><Citation>
FTiH (2023). “Phase 1 investigator-initiated trial (IIT) to evaluate the safety, feasibility,” in Cellular kinetics, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18. 2+ GI Tumors. Available at: https://clinicaltrials.gov/study/NCT05981235.
</Citation></Reference><Reference><Citation>Gardner R. A., Ceppi F., Rivers J., Annesley C., Summers C., Taraseviciute A., et al. (2019). Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood 134 (24), 2149–2158. 10.1182/blood.2019001463</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019001463</ArticleId><ArticleId IdType="pmc">PMC6908832</ArticleId><ArticleId IdType="pubmed">31697826</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazeau N., Liang E. C., Wu Q., Voutsinas J. M., Barba P., Iacoboni G., et al. (2023). Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant. Cell. Ther. 29 (7), 430–437. 10.1016/j.jtct.2023.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtct.2023.04.001</ArticleId><ArticleId IdType="pmc">PMC10330552</ArticleId><ArticleId IdType="pubmed">37031746</ArticleId></ArticleIdList></Reference><Reference><Citation>
GD2/PSMA Bi-specific CAR-T cells for the treatment of GD2 and PSMA positive solid tumors (2022). Available at: https://clinicaltrials.gov/study/NCT05437315

</Citation></Reference><Reference><Citation>Grosskopf A. K., Labanieh L., Klysz D. D., Roth G. A., Xu P., Adebowale O., et al. (2022). Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci. Adv. 8 (14), eabn8264. 10.1126/sciadv.abn8264</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abn8264</ArticleId><ArticleId IdType="pmc">PMC8993118</ArticleId><ArticleId IdType="pubmed">35394838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalos M., Levine B. L., Porter D. L., Katz S., Grupp S. A., Bagg A., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3 (95), 95ra73. 10.1126/scitranslmed.3002842</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002842</ArticleId><ArticleId IdType="pmc">PMC3393096</ArticleId><ArticleId IdType="pubmed">21832238</ArticleId></ArticleIdList></Reference><Reference><Citation>Korell F., Berger T. R., Maus M. V. (2022). Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Med 3 (8), 538–564. 10.1016/j.medj.2022.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.05.001</ArticleId><ArticleId IdType="pubmed">35963235</ArticleId></ArticleIdList></Reference><Reference><Citation>Labanieh L., Majzner R. G., Klysz D., Sotillo E., Fisher C. J., Vilches-Moure J. G., et al. (2022). Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185 (10), 1745–1763.e22. 10.1016/j.cell.2022.03.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.041</ArticleId><ArticleId IdType="pmc">PMC9467936</ArticleId><ArticleId IdType="pubmed">35483375</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin (2021). FDA emergency use authorized treatment protocol of DeltaRex-G for severe covid-19 [IND# 27185]. Eur. J. Respir. Med. 3 (2). 10.31488/EJRM.119</Citation><ArticleIdList><ArticleId IdType="doi">10.31488/EJRM.119</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Chawla S. P., Bruckner H., Morse M. A., Federman N., Srikureja A., et al. (2021). Long term survival following DeltaRex-G/DeltaVax tumor-targeted gene therapy for advanced chemotherapy-resistant malignancies: an academic milestone. Clin. Oncol. 6, 1807. 10.25107/2474-1663.1807</Citation><ArticleIdList><ArticleId IdType="doi">10.25107/2474-1663.1807</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Deng B., Yin Z., Pan J., Lin Y., Ling Z., et al. (2020). Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 10 (2), 15. 10.1038/s41408-020-0280-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-020-0280-y</ArticleId><ArticleId IdType="pmc">PMC7005173</ArticleId><ArticleId IdType="pubmed">32029707</ArticleId></ArticleIdList></Reference><Reference><Citation>Maude S. L., Barrett D., Teachey D. T., Grupp S. A. (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20 (2), 119–122. 10.1097/PPO.0000000000000035</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PPO.0000000000000035</ArticleId><ArticleId IdType="pmc">PMC4119809</ArticleId><ArticleId IdType="pubmed">24667956</ArticleId></ArticleIdList></Reference><Reference><Citation>Melero I., Castanon E., Alvarez M., Champiat S., Marabelle A. (2021). Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18 (9), 558–576. 10.1038/s41571-021-00507-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-021-00507-y</ArticleId><ArticleId IdType="pmc">PMC8130796</ArticleId><ArticleId IdType="pubmed">34006998</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mesothelin/GPC3/GUCY2C targeted CAR-T for immunotherapy of pancreatic cancer: phase I clinical trial. (2023). Available at: https://clinicaltrials.gov/study/NCT05779917

</Citation></Reference><Reference><Citation>Morse M., Chawla S., Wong T., Bruckner H., Hall F., Gordon E. (2021). Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: a case report and literature review. Mol. Clin. Oncol. 15 (3), 186. 10.3892/mco.2021.2348</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mco.2021.2348</ArticleId><ArticleId IdType="pmc">PMC8278409</ArticleId><ArticleId IdType="pubmed">34277005</ArticleId></ArticleIdList></Reference><Reference><Citation>
Open An. (2020). Multicenter, phase ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/gastroesophageal junction adenocarcinoma and. Pancreat. Cancer. Available at: https://clinicaltrials.gov/study/NCT04581473.
</Citation></Reference><Reference><Citation>
Open-Label An. (2022). Single-arm, dose-exploration study to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of CT048 in subjects with advanced solid tumors. Available at: https://clinicaltrials.gov/study/NCT05393986.
</Citation></Reference><Reference><Citation>
Phase I. (2022). II study of pan-T booster Co-expressing MSLN CAR T cell therapy in advanced/metastatic solid tumors. Available at: https://clinicaltrials.gov/study/NCT05693844.
</Citation></Reference><Reference><Citation>
Phase I clinical study of chimeric antigen receptor T cells (C-13-60) in the treatment of carcinoembryonic antigen (CEA) positive advanced malignant solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT06043466

</Citation></Reference><Reference><Citation>
Phase I study of autologous T Lymphocytes expressing GD2-specific chimeric antigen and constitutively active IL-7 receptors for the treatment of patients with relapsed or refractory neuroblastoma and other GD2 positive solid cancers(GAIL-N) (2018). Available at: https://clinicaltrials.gov/study/NCT03635632

</Citation></Reference><Reference><Citation>
Phase I/II study of anti-GD2 chimeric antigen receptor-expressing T cells in pediatric patients affected by high risk and/or relapsed/refractory neuroblastoma or other GD2-positive solid tumors (2017). Available at: https://clinicaltrials.gov/study/NCT03373097

</Citation></Reference><Reference><Citation>
Phase I/II study of CD70 targeted CAR-T cell treatment in CD70 positive advanced/metastatic solid tumors (2023). Available at: https://clinicaltrials.gov/study/NCT05947487

</Citation></Reference><Reference><Citation>
Phase I study of EGFR, Targeted tgfβr-KO CAR T cells in the treatment of previously treated advanced EGFR-positive solid tumors (2021). Available at: https://clinicaltrials.gov/study/NCT04976218

</Citation></Reference><Reference><Citation>Qin Y., Xu G. (2022). Enhancing CAR T-cell therapies against solid tumors: mechanisms and reversion of resistance. Front. Immunol. 13, 1053120. 10.3389/fimmu.2022.1053120</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1053120</ArticleId><ArticleId IdType="pmc">PMC9773088</ArticleId><ArticleId IdType="pubmed">36569859</ArticleId></ArticleIdList></Reference><Reference><Citation>Sermer D., Brentjens R. (2019). CAR T‐cell therapy: full speed ahead. Hematol. Oncol. 37 (S1), 95–100. 10.1002/hon.2591</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2591</ArticleId><ArticleId IdType="pubmed">31187533</ArticleId></ArticleIdList></Reference><Reference><Citation>
Single-center A. (2022a). “Open-label, single-arm clinical study of the safety and efficacy of KD-025 CAR-T therapy,” in Advanced NKG2DL+ solid tumors. Available at: https://clinicaltrials.gov/study/NCT05382377.
</Citation></Reference><Reference><Citation>
Single-center A. (2022b). Open-label, single-arm clinical study of the safety and efficacy of KD-496 CAR-T therapy in advanced nkg2dl+/CLDN18. 2+ Solid Tumors. Available at: https://clinicaltrials.gov/study/NCT05583201.
</Citation></Reference><Reference><Citation>
T cells armed with chimeric antigen receptor recognizing EpCAM for patients with advanced solid tumors (2016). Available at: https://clinicaltrials.gov/study/NCT02915445

</Citation></Reference><Reference><Citation>Ventin M., Cattaneo G., Maggs L., Arya S., Wang X., Ferrone C. R. (2024). Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review. JAMA Oncol. 10 (1), 115–121. 10.1001/jamaoncol.2023.4504</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2023.4504</ArticleId><ArticleId IdType="pubmed">37943567</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H., Li X., Gao W., Fu X., Fang R. H., Zhang L., et al. (2018). Tissue repair and regeneration with endogenous stem cells. Nat. Rev. Mater 3 (7), 174–193. 10.1038/s41578-018-0027-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-018-0027-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu I., Liu R., Garcia J. M., Hyrenius-Wittsten A., Piraner D. I., Alavi J., et al. (2022). Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185 (8), 1431–1443.e16. 10.1016/j.cell.2022.03.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.023</ArticleId><ArticleId IdType="pmc">PMC9108009</ArticleId><ArticleId IdType="pubmed">35427499</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>